Presentation: Improving mRNA Purity and Batch-to-Batch Consistency

January 28, 2026 by Aldevron

Optimizing mRNA Manufacturing

Ensuring mRNA purity, yield, and manufacturing consistency is a major challenge for developers seeking to scale mRNA production. From variability in full length purity (FLP) and the limitations of relying on a rigid, one-size-fits-all IVT platform, these issues can create operational inefficiencies and restrict knowledge accumulation across programs.

In his presentation at the 2025 International mRNA Health Conference, Venkata Indurthi, Ph.D., Chief Scientific Officer at Aldevron, discusses these challenges, then touches on steps Aldevron has taken to address them, including highlighting the company’s IVT screening, where 26 process variables were evaluated to unlock performance gains.

He touches on how the use of Codex® HiCap T7 enzyme delivered a 10x reduction in dsRNA, required 40% less CleanCap®, and drove major improvements in both FLP and overall yield.

Indurthi also covers downstream elements of the manufacturing process, such as advances that include elements such as improved buffers, optimized dilution, and low‑salt washes that can more than double recovery and increase FLP by 30% for large‑RNA constructs.

Downstream, Indurthi notes how the Aldevron team identified buffer and wash improvements that more than doubled recovery, increased FLP by 30%, and reduced losses from precipitation, especially critical for larger constructs prone to achieving under 60% FLP. Get the full picture in his presentation from the event.

Watch the Presentation

• Have questions on this topic? Contact Us
• Visit our RNA manufacturing page
• Have an idea for a topic? Let us know!

Subscribe to our blog